Botox may soon have a competitor that will could last longer.
Revance Therapeutics’ wrinkle-reducing injection met its goal of lasting for six months, according to phase three trial results the company released Tuesday. Competitors Allergan’s Botox Cosmetic as well as also also Galderma’s Dysport last up to four months, according to their websites.
Revance’s RT002 uses the same active ingredient as its competitors, botulinum toxin Type A, yet was created using the company’s proprietary peptide technology. The product can be 15 years from the creating as well as also also can be today one step closer to reaching consumers.
A long-term safety study can be already underway as well as also also can be required to conclude from the second half of next year. Revance plans to bring the injection to market in 2020, assuming the drug receives approval via the Food as well as also also Drug Administration.
“We believe today’s results not only validate the effectiveness as well as also also patient response yet substantiate RT002 injectable’s place as a distinctly completely new generation of long-acting neuromodulators,” Revance co-founder as well as also also CEO Dan Browne said Tuesday on a call outlining the study’s findings.
Allergan wasn’t as impressed. In a statement, that will called the results “underwhelming” as well as also also said that will doesn’t believe the data released Tuesday will support a claim that will RT002 lasts longer.
The company’s Botox injection was introduced for cosmetic use in 2002 as well as also also remains the market leader.
“Allergan continues to invest in neurotoxin research as well as also also development. The company’s continued investment includes potential future indications for Botox as well as also also Botox Cosmetic as well as next-generation neurotoxins,” the company said in an emailed statement.
Cantor Fitzgerald analyst Louise Chen said the data were “meaningfully better than expected by the Street” in a research note published Tuesday. Shares of Revance skyrocketed 33.7 percent Tuesday. They’ve today gained nearly 68 percent This kind of year.
Allergan’s stock, meanwhile, fell 1.5 percent as well as also also was trading at its lowest levels since December 2013. that will has shed nearly 22 percent on the year.